Order Article Reprints

Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, Tachibana T, Shinada M, Zhang M-R, Kurosawa G, et al. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized ⁶⁴Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. International Journal of Molecular Sciences. 2022; 23(10):5807. https://doi.org/10.3390/ijms23105807

Hihara, Fukiko, Hiroki Matsumoto, Mitsuyoshi Yoshimoto, Takashi Masuko, Yuichi Endo, Chika Igarashi, Tomoko Tachibana, Mitsuhiro Shinada, Ming-Rong Zhang, Gene Kurosawa, and et al. 2022. "In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized ⁶⁴Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study" International Journal of Molecular Sciences 23, no. 10: 5807. https://doi.org/10.3390/ijms23105807

Hihara, F., Matsumoto, H., Yoshimoto, M., Masuko, T., Endo, Y., Igarashi, C., Tachibana, T., Shinada, M., Zhang, M.-R., Kurosawa, G., Sugyo, A., Tsuji, A. B., Higashi, T., Kurihara, H., Ueno, M., & Yoshii, Y. (2022). In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized ⁶⁴Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study. International Journal of Molecular Sciences, 23(10), 5807. https://doi.org/10.3390/ijms23105807